With the mission of improving patient management in critical care settings, SphingoTec has started a series of collaboration with internationally leading academic and non-academic medical centers. The main goal of these collaborations is to implement tests for novel biomarkers in the clinical routine and hence translate science into medical practice.
SphingoTec has an international qualified network of distribution partners with which we work in close cooperation and mutual support. We are committed to providing our partners with exceptional levels of service and we are actively building long-term global relationships.
SphingoTec has established an extended intellectual property portfolio covering markers for acute care conditions such as sepsis, acute heart failure and acute kidney injury. All biomarkers are available for licensing to companies wishing to develop assays for clinical use on their immunoassay platforms.